New drug approvals from FDA declined in 2013

by Matthew Perrone

(AP)—The Food and Drug Administration approved fewer first-of-a-kind drugs in 2013 compared with 2012, when new drug approvals reached a 15-year high.

The agency approved 27 innovative medicines last year, down from the 39 new medications cleared the year before.

Despite the decline, FDA officials say last year's tally is in line with the historical trend. On average, the FDA has approved 28 first-of-a-kind drugs over the last five years.

FDA approvals are watched closely by analysts as a barometer of industry innovation and the government's efficiency in reviewing new therapies.

Experts say the number of declined in 2013 mainly because there were fewer drugs submitted for review.

1 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

US House sends drug bill to Senate for final vote

Jun 20, 2012

(AP) — The House on Wednesday passed a major bill affecting the Food and Drug Administration that will increase inspections of drug manufacturing facilities overseas, while also funding review of new drugs at home.

US health watchdog rejects Sanofi's MS drug

Dec 30, 2013

French drug giant Sanofi announced Monday US health authorities had rejected its Lemtrada drug for some forms of multiple sclerosis, which is already approved in the European Union, Canada and Australia.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments